Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma-SELEX for Acute Myocardial Infarction Biomarker Discovery and Diagnosis.

Analytical chemistry·2026
Same author

Hollow Mesoporous Silica Nanoparticles Co-Loaded with Docetaxel and Indocyanine Green for Synergistic Chemo-Photothermal Therapy.

Nanomaterials (Basel, Switzerland)·2026
Same author

Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly.

Journal of the American Chemical Society·2026
Same author

Author Correction: DNA nanodevices detect an acidic nanolayer on the lysosomal surface.

Nature cell biology·2026
Same author

Receptor-Tethered Cytosolic Modulators Enable Spatial Control of Cell Signaling Specificity.

ACS nano·2026
Same author

Late-Stage Carboranylation of Nucleos(t)ides Enabled by Minisci and Pd-Catalyzed B-N Cross-Coupling Reactions: Toward the Synthesis of Carboranyl-Modified Oligonucleotides.

Journal of the American Chemical Society·2026

Related Experiment Video

Updated: Sep 17, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.8K

Cordycepin: a dual-function molecular element for aptamer engineering with enhanced anticancer activity.

Fei Gao1, Li Na1, Shuyue Fu1

  • 1Institute of Translation Medicine, School of Life Science, Shanghai University Shanghai 200444 China heshipeng@shu.edu.cn.

Chemical Science
|July 2, 2025
PubMed
Summary

Cordycepin, a compound from Cordyceps sinensis, was modified into aptamer-drug conjugates for cancer therapy. The Sgc8-23A conjugate showed enhanced antitumor activity and stability, demonstrating potential for targeted cancer treatment.

More Related Videos

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

6.1K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.7K

Related Experiment Videos

Last Updated: Sep 17, 2025

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

3.8K
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

6.1K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.7K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Cordycepin (3'-deoxyadenosine, 3'-dA) exhibits bioactivity as an enzyme inhibitor but lacks sufficient therapeutic efficacy for clinical use.
  • Targeted delivery systems are crucial for enhancing cordycepin's therapeutic potential.
  • Aptamers are promising tools for targeted drug delivery in cancer therapy.

Purpose of the Study:

  • To design and synthesize a 3'-dA phosphoramidite for incorporating cordycepin into the Sgc8c aptamer.
  • To create novel aptamer-drug conjugates (ADCs) with cordycepin as both a structural modulator and a bioactive component.
  • To evaluate the antitumor activity and stability of cordycepin-modified aptamers.

Main Methods:

  • Synthesis of a 3'-dA phosphoramidite for cordycepin integration into aptamers.
  • Generation of cordycepin-modified aptamers, including Sgc8-23A.
  • In vitro assessment of antitumor activity against HCT116 human colon cancer cells.
  • In vivo evaluation using a zebrafish patient-derived xenograft (PDX) model.

Main Results:

  • Cordycepin was successfully incorporated into the Sgc8c aptamer, creating functional ADCs.
  • The Sgc8-23A aptamer-drug conjugate demonstrated enhanced antitumor activity compared to free cordycepin.
  • Sgc8-23A exhibited superior bioactivity and stability.
  • Significant tumor growth inhibition was observed in the zebrafish PDX model with Sgc8-23A treatment.

Conclusions:

  • Cordycepin-modified aptamers, like Sgc8-23A, offer a dual function as structural aptamer modulators and therapeutic agents.
  • These aptamer-drug conjugates show significant potential for targeted cancer therapy.
  • The findings support the development of advanced aptamer-based drug delivery systems for improved cancer treatment.